Targeting of CD34⁺CD38^- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

<p>Abstract</p> <p>Background</p> <p>The CD34⁺CD38^- subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment.</p> <p>Me...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jawad Mays, Yu Ning, Seedhouse Claire, Tandon Karuna, Russell Nigel H, Pallis Monica
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2012-09-01
Цуврал:	BMC Cancer
Нөхцлүүд:	Tipifarnib/Zarnestra Gemtuzumab ozogamicin/ Mylotarg AML CD34<sup>+</sup>CD38<sup>-</sup> cells DNA damage response
Онлайн хандалт:	http://www.biomedcentral.com/1471-2407/12/431
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!